



# WEEKLY WRAP-UP

07<sup>TH</sup> APRIL - 11<sup>TH</sup> APRIL 2025

**PROGRESSIVE**<sup>®</sup>  
Your Progress Our Priority...

Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking



**07 Apr 2025-11 Apr 2025**

- HDFC Bank reduces marginal cost of fund-based lending rates by 10bps across tenures
- Vodafone Idea expands 5G services to cricket stadiums across 11 cities
- Mahindra expands India Design Studio to cater to evolving needs
- Prestige hotels arm to file for Rs2,000-2,500cr IPO this month
- NCLAT rejects IDBI Bank's insolvency plea against Zee over Rs150cr dues
- BEL receives Rs22.1bn order from Indian Air Force
- Lemon Tree signs license agreement for Keys Prima Hotel in Darjeeling
- KPI Green informed termination of 66.20MW Hybrid Power Project under CPP segment
- Bajaj Healthcare acquires Genrx Pharmaceuticals for Rs108.5mn
- BPCL, Sembcorp form JV to boost green hydrogen transition and renewable energy in India
- Adani Wilmar to be renamed AWL Agri Business from 16th April
- Signature Global reports 42% y-o-y growth in pre-sales in FY25
- Indian Oil to invest Rs61,000cr to build petchem complex in Odisha
- Unilever's ex-ice cream unit to set up its first global centre in Pune with Rs900cr investment
- Lupin going beyond the pill to grow its digital therapeutics arm
- Bharat Forge on edge as India-US trade pact holds the key
- ITC to benefit as govt. relaxes FDI rules for 'prohibited' sectors
- Jio Finance launches loan against security offering for customers
- Concord Biotech receives USFDA approval for Teriflunomide tablets
- Sasken acquires 100% of BORQS International for USD40mn
- Reliance BP & Nayara Energy fuel sales outgrow PSU peers'
- JSW Neo Energy completes acquisition of 4.7GW renewable energy platform from O2 Power
- Tata Steel to cut 1,600 Dutch jobs to save EUR500mn in costs
- Infosys extends collaboration with AIB for digital transformation
- Natco to sell rare spinal disease drug Risdiplam for Rs15,900
- BHEL signs MoU with Nuovo Pignone for compressor revamp
- NBCC sells 1,185 residential units for Rs15,046.9mn
- Bank of Baroda passes on 25bps rate cut to customers

- India-EU FTA soon with tariff cuts on merchandise
- RBI's Rs80k-cr infusion via OMOs raises rate-cut hopes
- RBI cuts repo by 25bps as tariffs cloud growth view

- Oil companies may mop up Rs9,000cr via LPG price hike, higher petrol, diesel excise duty
- RBI rate cut will have positive impact on auto sector: SIAM
- Steelmakers flex pricing power as imports decline

## HIGHLIGHTS OF THE WEEK

07 Apr 2025-11 Apr 2025

### COVERAGE NEWS:

**Aurobindo Pharma Ltd:** (i) The European Commission (EC) has granted marketing authorization for Dyrupreg, a pegylated filgrastim biosimilar, to CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, (ii) CuraTeQ Biologics Pvt. Ltd (WoS of Aurobindo) has successfully met the primary endpoints in a comprehensive pharmacokinetic (PK) and pharmacodynamic (PD) study for its biosimilar denosumab, BP16.

**KSB Ltd:** (i) received LOA under Magel Tyala Saur Krushi Pump Scheme (from Maharashtra State Electricity Distribution Co. Ltd) of approx. Rs490mn for 2000 solar water pumping systems. The sales/supply of products/services for these orders is expected from Q2-2025, (ii) received LOA under PM-Kusum Scheme (from Tripura Renewable Energy Development Agency) of approx. Rs140mn for 962 solar water pumping systems. The sales/supply of products/services for these orders is expected from Q2-2025.

**Sun Pharmaceutical Industries Ltd:** (i) SUNP alongwith its subsidiaries and/or associate companies has launched Fexuprazan tablets 40mg in India under the brand name Fexuclue and has obtained the rights from Daewoong Pharmaceutical Co. Ltd. Daewoong will be entitled to upfront and milestone payments, including royalties, (ii) For Leqselvi, the US Court of Appeals ruled in favour of SUNP and vacated the preliminary injunction effective immediately. While the litigation between Incyte Corporation and SUNP continues, the preliminary injunction is no longer in effect. SUNP is no longer under a court order that delays or restricts it from launching Leqselvi.

**Lloyds Engineering Works Ltd:** In the board meeting held on 08th April, 2025, there has been deferment of the rights issue agenda items, after considering the current volatile international market scenario and its likely impact on the proposed rights issue.

**Timken India Ltd:** The company has informed of formally inaugurating the new plant at Bharuch on 9th Apr'25 with commercial production expected to commence in Q1FY26.

**Metropolis Healthcare Ltd:** Metropolis Histoxpert Digital Services Pvt. Ltd, a WoS of Metropolis has entered into a BTA with Dr. Ahujas' Pathology & Imaging Centre (DAPIC, a partnership firm), Dr. Alok Ahuja and Dr. Alka Ahuja (sole proprietary firm) for acquisition of their entire business for a cash consideration of Rs350mn.

**Sejal Glass Ltd:** The Board has approved the proposed execution of BTA with Glasstech Industries (India) Pvt. Ltd for acquiring their business pertaining to manufacturing facilities & sale and supply of architectural glass & glass related products from its factories situated at Taloja, Maharashtra & Erode, Tamil Nadu, inclusive of technical know-how, intellectual property rights, brand name and goodwill for a cash consideration of Rs346mn, to be completed by 31st May, 2025.

**Sterlite Technologies Ltd:** (i) The company has partnered with Swoop Holdings Ltd to upgrade ~1,000 homes in Western Australia with high-speed Fibre-to-the-Home (FTTH) connectivity. Under this partnership, STL will supply state-of-the-art optical networking and connectivity solutions and further strengthen the digital infrastructure in the region, (ii) With regard to the scheme of demerger, STL Networks Ltd (the resulting company) shall issue and allot 1 fully paid equity share of Rs2 each for every 1 fully paid equity share of Rs2 each held in STL (the demerged entity). The record date for the same is set at 24th April, 2025.

**Shilpa Medicare Ltd:** The company has received USFDA approval for Varenicline tablets, 0.5/1mg. The total US market for the tablet is around USD203mn.

**Olectra Greentech Ltd:** The company has received an LOA worth Rs4240mn from Himachal Road Transport Corporation (HRTC) for supply and maintenance of 297 electric buses.

**Cipla Ltd:** The company has received USFDA final approval for Paclitaxel protein-bound particles for injectable suspension, 100mg/vial, single-dose vial. The product is expected to be launched in H1FY26 in the US.

### The Week That Went By:

The week on Dalal Street was marked by a seesaw trend, driven largely by global developments and volatile sentiment. The imposition of tariffs by the US President triggered a sharp sell-off in global markets, with Indian markets mirroring the trend—Nifty50 plunged over 1,000 points on the opening day, however, a strong recovery from lower levels followed. An oversold technical set-up led to a relief rally on the second trading session, but the higher levels did not last for long as fresh selling pressure emerged during the weekly expiry session. Sentiment turned positive again after the US President announced the 90-day pause on tariffs, sparking optimism and helping markets stage a sharp rebound on the final trading day. Nonetheless, Nifty50 ended the week slightly lower, closing with a loss of 75.90 points at 22,828.55. Sector-wise, FMCG and Media outperformed, showing resilience amid the volatility, while the Realty and IT sectors corrected the most.

Nifty50=22,828.55

BSE Sensex30=75,157.26

Nifty Midcap 100=50,501.50

Nifty Smallcap100=15,696.10

**07 Apr 2025-11 Apr 2025**

**NIFTY (WEEKLY)**



### BANK FIFTY (WEEKLY)



## MARKET OUTLOOK

The Bullish Belt Hold candlestick pattern observed on the weekly chart of **Nifty50** signifies a strong recovery by the bulls amidst highly volatile market conditions; further supported by a probable bullish divergence seen in the RSI. To maintain this positive momentum, the Index needs to decisively break above its immediate resistance of 50DMA, placed at 22,960. A successful breach would then lead the Index towards the next resistance at 23,170. Conversely, 22,670 serves as an immediate support, and a breakdown below this level may pull the Index down to 22,400. In the case of **BankNifty**, the zone of 51,350-51,890 is expected to act as a strong supply area, while nearby support lies at 50,500. The **Auto sector**, showing signs of a trend reversal, has rebounded from the lower end of a **Falling Wedge pattern**, with several constituents moving in alignment, reinforcing the shift. The **Energy sector** also witnessed a strong bounce back from its long-term trendline, though it must surpass the key hurdle at 34,100 to validate its uptrend. Meanwhile, **FMCG sector** is poised for a breakout from a **Falling Channel pattern**, with multiple indicators already signaling bullish potential; however, confirmation through next week's price action remains awaited. The **Metal sector** managed to hold its long-term trendline support, but the upcoming market sessions will be crucial for its direction. Although global uncertainties may ease due to the **90-day tariff pause** announced by the US President, domestic triggers such as **IIP, CPI, WPI data and quarterly earnings** are expected to drive the investor sentiment and contribute to volatility in the upcoming truncated trading week.




## HIGHLIGHTS OF THE WEEK

07 Apr 2025-11 Apr 2025

### NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	(0.75%)	HDFC Life	(0.16%)	ONGC	1.81%
Adani Ports	0.87%	Hero Motocorp	0.02%	PowerGrid	3.28%
Apollo Hospital	0.94%	Hindalco	0.30%	Reliance	1.17%
Asian Paints	1.72%	HUL	5.29%	SBI Life	0.92%
Axis Bank	(1.96%)	ICICI Bank	(1.72%)	SBIN	(1.97%)
Bajaj Auto	1.03%	IndusInd Bank	1.21%	ShriRam Finance	(2.33%)
Bajaj Finance	1.80%	INFY	(2.70%)	Sun Pharma	(1.00%)
Bajaj Finserv	1.97%	ITC	3.10%	Tata Consumer	1.10%
BEL	1.71%	JioFin	3.53%	Tata Motors	(3.11%)
Bharti Airtel	1.15%	JSW Steel	(1.55%)	Tata Steel	(5.12%)
Cipla	2.99%	Kotak Bank	(1.04%)	TCS	(2.02%)
Coal India	1.65%	LT	(4.29%)	Tech Mahindra	(2.86%)
Dr. Reddy's Labs	(0.36%)	M&M	(0.03%)	TITAN	5.07%
Eicher Motors	1.89%	Maruti	1.11%	Trent	(14.06%)
Eternal	2.63%	Nestle India	4.27%	Ultratech	0.00%
Grasim	1.38%	NTPC	2.52%	Wipro	(2.65%)
HCL Tech	(2.35%)				
HDFC Bank	(0.64%)				

### SECTORAL PERFORMANCE




## HIGHLIGHTS OF THE WEEK

07 Apr 2025-11 Apr 2025


### Weekly Derivative:

Following the tariff war-induced volatility, Indian equities have found some respite, witnessing a brief positive momentum. However, the broader trend remains uncertain, especially with a truncated trading week ahead. Open Interest (OI) data indicates that the 23,000 strike is a key resistance level, with the highest concentration of Call writing seen at this point. On the downside, the 22,500 strike serves as a strong support zone, backed by significant Put OI. Notably, the 22,800 level emerges as a pivotal range, with substantial OI built up on both sides. This suggests that Nifty may oscillate within the 22,500-23,000 range unless a breakout occurs. In Bank Nifty, the 51,000 strike stands out as a decisive level, with the highest Call and Put writing concentrated at this point-highlighting market indecisiveness. A move above this level may face resistance near 51,500, while support is expected around the 50,500 mark.

**Nifty OI Concentration Weekly**




**OI Change In Weekly**




### BANK NIFTY

**BankNifty OI Concentration Weekly**



**OI Change In Weekly**



**Top Long Build Up**

Name	LTP	% change	OI	% OI
PIIND	3621.50	9.65	1883750	28.38
INOXWIND	151.80	7.51	6359700	23.95
CAMS	3706.50	3.21	1887375	23.28
DEEPAKNTR	1922.05	6.56	1505700	18.76

**Top Short Build Up**

Name	LTP	% change	OI	% OI
COFORGE	6337.60	(0.10)	4047000	14.27
MUTHOOTFIN	2019.75	(5.77)	5132325	12.94
ICICIGI	1708.75	(4.59)	6948250	9.29
TORNTPHARM	3133.20	(0.06)	2450500	7.90

## HIGHLIGHTS OF THE WEEK

07 Apr 2025-11 Apr 2025

### SECTORAL GAINER



With gains of 3.55%, the **FMCG segment** outperformed the Benchmark Index. Barring **Dabur (0.18%)**, all the components ended the week in green, with **Britannia (+6.21%)** and **Godrej CP (+5.91%)** being the top performers, followed by **HUL (+5.29%)** and **Nestle (+4.27%)**. As shown in the chart, the sector is poised for a breakout from a **Falling Channel pattern**, with multiple indicators already signaling bullish potential; however, confirmation through next week's price action remains awaited.

### SECTORAL LOSER



The **Realty sector** corrected by 4% and underperformed Nifty50. Except for **Raymond (+1.31%)**, all the constituents concluded the week with a loss, where **Phoenix (6.40%)** and **Godrej Properties (5.87%)** tumbled the most.

## HIGHLIGHTS OF THE WEEK

07 Apr 2025-11 Apr 2025

### DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

#### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

#### Compliance Officer:

Ms. Neha Oza,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500.

#### Grievance Officer:

Email: grievancecell@progressiveshares.com